Expanded Access for IMMU-132
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: Metastatic Triple-Negative Breast Carcinoma
Interventions: DRUG: IMMU-132
Sponsor: Gilead Sciences